Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G)

Vaccine

Volumn 18, Issue 18, 2000, Pages 1944-1951

  Morris, Cindy B ^a   Cheng, Elly ^a   Thanawastien, Ann ^a   Cárdenas Freytag, Lucia ^a   Clements, John D ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvants; CTL; Cytokines; HIV vaccines; Mucosal vaccines

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BACTERIAL TOXINS; CYTOKINES; ENTEROTOXINS; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI PROTEINS; FEMALE; HIV ENVELOPE PROTEIN GP160; HIV-1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NASAL MUCOSA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS;

EID: 0033997662     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00447-8     Document Type: Article

References (33)

1. Haynes B.F. HIV vaccines: where we are and where we are going. Lancet. 348:1996;933-937.
2. Heeney J.L. AIDS. A disease of impaired TH-cell renewal? Immunol. Today. 16:1995;515-520.
3. Kahn J.O., Steimer K.S., Baenziger J., et al. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171:1995;1343-1347.
4. McElrath M.J., Corey L., Greenberg P.D., et al. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA. 93:1996;3972-3977.
5. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 6:1988;269-277.
6. Elson C.O. Cholera toxin and its subunits as potential oral adjuvants. Immunol. Today. 146:1989;29-33.
7. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:1992;2277-2281.
8. Xu-Amano J., Kiyono H., Jackson R.J., et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosal associated tissues. J. Exp. Med. 178:1993;1309-1320.
9. Yamamoto M., Vancott J.L., Okahashi N., et al. The role of Th1 and Th2 cells for mucosal IgA responses. Ann. NY Acad. Sci. 778:1996;64-71.
10. Xu-Amano J., Jackson R.J., Fujihashi K., Kiyono H., Staats H.F., McGhee J.R. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine. 12:1994;903-911.
11. Hashigucci K., Ogawa H., Ishidate T., et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 14:1996;113-119.
12. Katz J.M., Lu X., Galphin J.C., Clements J.D. Heat-labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination. Brown L.E., Hampson A.W., Webster R.G., Brown L.E., Hampson A.W., Webster R.Gs. Options for the control of influenza. III. 1996;292-297 Elsevier Science, New York.
13. Katz J.M., Lu X., Young S.A., Galphin J.C. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 175:1997;352-363.
14. Lee C.K., Weltzin R., Thomas W.D., et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 172:1995;161-171.
15. Weltzin R., Kleanthous H., Guirakhoo F., Monath T.P., Lee C.K. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine. 4:1997;370-376.
16. Wu Y.-Y., Nahm M.H., Guo Y., Russell M.W., Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:1997;839-846.
17. Mason H.S., Ball J.M., Shi J.-J., Jiang X., Estes M.K., Arntzen C.J. Expression of Norwalk virus capsid protein in transgenic tobacco and potato plants and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA. 93:1996;5335-5340.
18. Hathaway L.J., Partidos C.D., Vohra P., Steward M.W. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Vaccine. 13:1995;1495-1500.
19. Staats H.F., Nichols W.G., Palker T.J. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 157:1996;462-472.
20. Freytag L.C., Clements J.D. Bacterial toxins as mucosal adjuvants. Kraehenbuhl J.P., Neutra M.R., Kraehenbuhl J.P., Neutra M.Rs. Defense of mucosal surfaces: Pathogenesis, immunity and vaccines. 1998;215-236 Springer, New York.
21. Levine M.M., Kaper J.B., Black R.E., Clements M.L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:1983;510-550.
22. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1995;1617-1623.
23. Cárdenas-Freytag L., Cheng E., Mayeux P., Domer J.E., Clements J.D. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immun. 67:1999;826-833.
24. Chong C., Friberg M., Clements J.D. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine. 16:(7):1998;732-740.
25. O'Neal C.M., Clements J.D., Estes M.K., Conner M.E. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge [In Process Citation]. J. Virol. 72:(4):1998;3390-3393.
26. Kalyanaraman V.S., Pal R., Gallo R.C., Sarngadharan G. A unique human immunodeficiency virus culture secreting soluble gp160. AIDS Res. Hum. Retroviruses. 4:1988;319-329.
27. Kalyanaraman V.S., Rodriguez V., Veronese F., et al. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 6:1990;371-380.
28. Kalyanaraman V.S., Rodriguez V., Josephs S., Gallo R.C., Sarngadharan M.G. Differential viral gene expression and its effect of the biological properties of the cell clones of an HIV-1 infected cell line. Virol. 177:1990;380-383.
29. Takeshita T., Takahashi H., Kozlowski S., et al. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J. Immunol. 154:(4):1995;1973-1986.
30. Cheng E, Cárdenas-Freytag L, Clements JD. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 1999;18:38-49.
31. Frey S.E. HIV vaccines [In Process Citation]. Infect. Dis. Clin. North Am. 13:(1):1999;95-112.
32. Letvin N.L. Progress in the development of an HIV-1 vaccine [see comments]. Science. 280:(5371):1998;1875-1880.
33. Vancott T.C., Kaminski R.W., Mascola J.R., et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 160:(4):1998;2000-2012.